213 related articles for article (PubMed ID: 7966611)
1. Distribution of drug resistance mutations in type 3 poliovirus identifies three regions involved in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
J Virol; 1994 Dec; 68(12):8193-201. PubMed ID: 7966611
[TBL] [Abstract][Full Text] [Related]
2. Mutations in the poliovirus P1 capsid precursor at arginine residues VP4-ARG34, VP3-ARG223, and VP1-ARG129 affect virus assembly and encapsidation of genomic RNA.
Ansardi DC; Luo M; Morrow CD
Virology; 1994 Feb; 199(1):20-34. PubMed ID: 8116243
[TBL] [Abstract][Full Text] [Related]
3. Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus.
Salvati AL; De Dominicis A; Tait S; Canitano A; Lahm A; Fiore L
Antimicrob Agents Chemother; 2004 Jun; 48(6):2233-43. PubMed ID: 15155227
[TBL] [Abstract][Full Text] [Related]
4. Allele-specific adaptation of poliovirus VP1 B-C loop variants to mutant cell receptors.
Liao S; Racaniello V
J Virol; 1997 Dec; 71(12):9770-7. PubMed ID: 9371643
[TBL] [Abstract][Full Text] [Related]
5. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
6. Use of drug-resistance mutants to identify functional regions in picornavirus capsid proteins.
Mosser AG; Shepard DA; Rueckert RR
Arch Virol Suppl; 1994; 9():111-9. PubMed ID: 8032243
[TBL] [Abstract][Full Text] [Related]
7. Early events in poliovirus infection: virus-receptor interactions.
Racaniello VR
Proc Natl Acad Sci U S A; 1996 Oct; 93(21):11378-81. PubMed ID: 8876143
[TBL] [Abstract][Full Text] [Related]
8. WIN 51711-dependent mutants of poliovirus type 3: evidence that virions decay after release from cells unless drug is present.
Mosser AG; Rueckert RR
J Virol; 1993 Mar; 67(3):1246-54. PubMed ID: 8382293
[TBL] [Abstract][Full Text] [Related]
9. Poliovirus capsid proteins derived from P1 precursors with glutamine-valine cleavage sites have defects in assembly and RNA encapsidation.
Ansardi DC; Morrow CD
J Virol; 1993 Dec; 67(12):7284-97. PubMed ID: 8230452
[TBL] [Abstract][Full Text] [Related]
10. The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.
Hadfield AT; Lee Wm; Zhao R; Oliveira MA; Minor I; Rueckert RR; Rossmann MG
Structure; 1997 Mar; 5(3):427-41. PubMed ID: 9083115
[TBL] [Abstract][Full Text] [Related]
11. WIN51711-resistant mutants of poliovirus type 3: capsid residues important in uncoating functions.
Mosser AG; Sgro JY; Rueckert RR
Acta Crystallogr D Biol Crystallogr; 1995 Jul; 51(Pt 4):490-5. PubMed ID: 15299835
[TBL] [Abstract][Full Text] [Related]
12. A Single Amino Acid Substitution in Poliovirus Nonstructural Protein 2CATPase Causes Conditional Defects in Encapsidation and Uncoating.
Asare E; Mugavero J; Jiang P; Wimmer E; Paul AV
J Virol; 2016 Jul; 90(14):6174-6186. PubMed ID: 27076638
[TBL] [Abstract][Full Text] [Related]
13. Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.
Grant RA; Hiremath CN; Filman DJ; Syed R; Andries K; Hogle JM
Curr Biol; 1994 Sep; 4(9):784-97. PubMed ID: 7820548
[TBL] [Abstract][Full Text] [Related]
14. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14.
Shepard DA; Heinz BA; Rueckert RR
J Virol; 1993 Apr; 67(4):2245-54. PubMed ID: 8383239
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of mouse-virulent poliovirus type 1 Mahoney mutants: involvement of residues of polypeptides VP1 and VP2 located on the inner surface of the capsid protein shell.
Couderc T; Hogle J; Le Blay H; Horaud F; Blondel B
J Virol; 1993 Jul; 67(7):3808-17. PubMed ID: 8389907
[TBL] [Abstract][Full Text] [Related]
16. Myristate-protein interactions in poliovirus: interactions of VP4 threonine 28 contribute to the structural conformation of assembly intermediates and the stability of assembled virions.
Moscufo N; Chow M
J Virol; 1992 Dec; 66(12):6849-57. PubMed ID: 1331497
[TBL] [Abstract][Full Text] [Related]
17. An antiviral compound that blocks structural transitions of poliovirus prevents receptor binding at low temperatures.
Dove AW; Racaniello VR
J Virol; 2000 Apr; 74(8):3929-31. PubMed ID: 10729171
[TBL] [Abstract][Full Text] [Related]
18. Structure of poliovirus type 2 Lansing complexed with antiviral agent SCH48973: comparison of the structural and biological properties of three poliovirus serotypes.
Lentz KN; Smith AD; Geisler SC; Cox S; Buontempo P; Skelton A; DeMartino J; Rozhon E; Schwartz J; Girijavallabhan V; O'Connell J; Arnold E
Structure; 1997 Jul; 5(7):961-78. PubMed ID: 9261087
[TBL] [Abstract][Full Text] [Related]
19. Mutations in VP1 of poliovirus specifically affect both encapsidation and release of viral RNA.
Kirkegaard K
J Virol; 1990 Jan; 64(1):195-206. PubMed ID: 2152812
[TBL] [Abstract][Full Text] [Related]
20. Host range determinants located on the interior of the poliovirus capsid.
Moss EG; Racaniello VR
EMBO J; 1991 May; 10(5):1067-74. PubMed ID: 1850692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
